{
  "image_filename": "table_p11_det_10_013.png",
  "image_path": "Liu_et_al.__2024_/extracted/figures/table_p11_det_10_013.png",
  "image_type": "Table",
  "page_number": 11,
  "block_id": "det_10_013",
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "supports_claim": false,
  "explanation": "A table presenting demographic characteristics of study participants by vaccine group, including mean age, age group distribution, sex, race/ethnicity, study site, and prior influenza vaccination history for four vaccine groups: Fluzone IIV4, Fluarix IIV4, cell-culture IIV4, and recombinant IIV4. does not support the claim because the table only provides demographic and prior vaccination history data, not antibody response or immunogenicity outcomes. Note: The table does not include any immunogenicity or antibody response data.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table presenting demographic characteristics of study participants by vaccine group, including mean age, age group distribution, sex, race/ethnicity, study site, and prior influenza vaccination history for four vaccine groups: Fluzone IIV4, Fluarix IIV4, cell-culture IIV4, and recombinant IIV4.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only provides demographic and prior vaccination history data, not antibody response or immunogenicity outcomes.",
    "confidence_notes": "The table does not include any immunogenicity or antibody response data."
  }
}